Immunotherapy — targeted drug combination improves survival in advanced kidney cancer

Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug according to the results from a phase 3 clinical trial.


Click here for original story, Immunotherapy — targeted drug combination improves survival in advanced kidney cancer


Source: ScienceDaily